idarubicin has been researched along with Minimal Disease, Residual in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (15.15) | 18.2507 |
| 2000's | 16 (48.48) | 29.6817 |
| 2010's | 10 (30.30) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Elonen, E; Huhtala, H; Itälä-Remes, M; Jantunen, E; Kairisto, V; Kauppila, M; Koistinen, P; Koivunen, E; Kolonen, A; Kuittinen, T; Nousiainen, T; Ollikainen, H; Pelliniemi, TT; Penttilä, K; Porkka, K; Pyörälä, M; Räty, R; Rauhala, A; Rimpiläinen, J; Rintala, H; Ruutu, T; Säily, M; Sankelo, M; Silvennoinen, R; Sinisalo, M; Volin, L | 1 |
| Gong, L; Huang, X; Jia, J; Jiang, H; Jiang, Q; Lai, Y; Liu, K; Liu, X; Lu, R; Lu, S; Ruan, G; Shi, H; Wang, J; Wang, Y; Wu, Y; Xu, L; Yan, C; Zhang, X; Zhao, X | 1 |
| Ballerini, F; Cagnetta, A; Carminati, E; Cea, M; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Matarese, S; Miglino, M; Minetto, P; Raiola, AM | 1 |
| Fang, J; Li, J; Lu, X; Shi, W; Wang, H; Wu, Q; Xia, L; You, Y; Zang, S; Zhang, C; Zhang, R; Zhong, Z | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Basso, G; Beqiri, V; Bisio, V; Buldini, B; Fagioli, F; Locatelli, F; Manara, E; Masetti, R; Pession, A; Pigazzi, M; Putti, MC; Rizzari, C; Rondelli, R; Tregnago, C | 1 |
| Grimwade, D; Kayser, S; Schlenk, RF; Walter, RB; Yosuico, VE | 1 |
| Brunet, S; Castro, N; Chillón, MC; Díez-Campelo, M; González, M; Herrera, P; López, J; Mateo, M; Mateos, MV; Montesinos, P; Ocio, EM; Olave, MT; Oriol, A; Pérez-Simón, JA; Prieto-Conde, MI; San Miguel, JF; Sanz, MÁ; Vidriales, MB | 1 |
| Andreeff, M; Borthakur, G; Brandt, M; Cortes, J; Daver, N; DiNardo, C; Estrov, Z; Garcia-Manero, G; Huang, X; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, H; Konoplev, S; Konopleva, M; Pierce, S; Ravandi, F; Wang, S; Wang, X | 1 |
| Hayakawa, M; Ichihashi, T; Iida, H; Iino, M; Kiyoi, H; Naoe, T; Narimatsu, H; Sawamoto, A; Sugiura, I; Suzuki, R; Takeo, T; Tsuzuki, M; Yanada, M; Yokozawa, T | 1 |
| Asano, H; Hangaishi, A; Hosoi, M; Kurokawa, M; Takahashi, T; Yamamoto, G | 1 |
| Andresen, S; Bolwell, B; Chan, J; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sproat, L; Sweetenham, J; Tench, S | 1 |
| Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG | 1 |
| Amadori, S; Buccisano, F; Coco, FL; Consalvo, MI; Cudillo, L; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Franchi, A; Lo-Coco, F; Maurillo, L; Mazzone, C; Picardi, A; Tamburini, A; Venditti, A | 1 |
| Breccia, M; Damiani, D; Diverio, D; Lo Coco, F; Locatelli, F; Marmont, F; Noguera, NI; Petti, MC; Santoro, A; Vignetti, M; Visani, G | 1 |
| Borkhardt, A; Bruch, J; Fuchs, U; Metzler, M; Perez, AV; Wilda, M; Woessmann, W | 1 |
| Hayashi, Y; Kanazawa, T; Morikawa, A; Ogawa, C; Taketani, T; Taki, T | 1 |
| Döhner, H; Döhner, K; Eiwen, K; Fröhling, S; Schlenk, RF; Scholl, C | 1 |
| Escherich, G; Hassenpflug, WA; Horstmann, MA; Janka, G; Kabisch, H; zur Stadt, U | 1 |
| Cho, SG; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Li, JY; Qian, SX; Qiu, HR; Shen, RL; Wu, YJ; Zhang, JF; Zhang, SJ; Zhou, HF | 1 |
| Alvarez, C; Bolufer, P; Brunet, S; Colomer, D; Díaz-Mediavilla, J; Escoda, L; Esteve, J; González San Miguel, JD; González, M; Martín, G; Rivas, C; Rubio, V; Sánchez Godoy, P; Sanz, MA; Sayas, MJ; Tomás, JF; Tormo, M | 1 |
| Balanzategui, A; Chillón, MC; Fernández, C; García Sanz, R; González, MG; Martín-Jiménez, P; San Miguel, JF; Santamaría, C | 1 |
| Amadori, S; Buccisano, F; Consalvo, MI; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Fraboni, D; Maurillo, L; Mazzone, C; Neri, B; Ottaviani, L; Panetta, P; Sarlo, C; Spagnoli, A; Tamburini, A; Venditti, A | 1 |
| D'Onofrio, G; Di Mario, A; Etuk, B; Leone, G; Salutari, P; Sica, S | 1 |
| Caron, PC; Finn, RD; Jurcic, JG; Larson, SM; Maslak, P; Miller, WH; Scheinberg, DA; Warrell, RP; Yao, TJ | 1 |
| Avvisati, G; Barbui, T; Bernasconi, C; Biondi, A; Broccia, G; Cerri, R; Diverio, D; Falda, M; Fioritoni, G; Jehn, U; Leoni, F; Liso, V; Lo Coco, F; Luciano, A; Mandelli, F; Muus, P; Pelicci, PG; Petti, MC; Rodeghiero, F; Saglio, G; Vegna, ML; Visani, G; Willemze, R | 1 |
| Avvisati, G; Capria, S; Diverio, D; Lo Coco, F; Mandelli, F; Meloni, G; Petti, MC; Vignetti, M | 1 |
| D'Elia, G; Diverio, D; Mandelli, F; Martinelli, G; Ottaviani, E; Testoni, N; Tura, S; Visani, G | 1 |
| Boros, B; Egyed, M; Földi, J; Páldi-Haris, P; Rumi, G | 1 |
| Au, WY; Chim, CS; Kwong, YL; Liang, R; Pang, A; Suen, C | 1 |
| Crooks, RL; Granter, N; Lincz, LF; Spencer, A; Way, SL | 1 |
1 review(s) available for idarubicin and Minimal Disease, Residual
| Article | Year |
|---|---|
Minimal residual disease-directed therapy in acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; RUNX1 Translocation Partner 1 Protein | 2015 |
8 trial(s) available for idarubicin and Minimal Disease, Residual
| Article | Year |
|---|---|
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Finland; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Prospective Studies; Remission Induction; Thioguanine | 2022 |
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Idarubicin; Indoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Neoplasm, Residual; Panobinostat; Prognosis; Recurrence; Treatment Outcome | 2015 |
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Longitudinal Studies; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Predictive Value of Tests; Probability; Recurrence; Risk Assessment; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome | 2003 |
The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Female; Humans; Idarubicin; Kinetics; Leukemia, Promyelocytic, Acute; Life Tables; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Survival Analysis; Tretinoin | 2006 |
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Oncogene Proteins, Fusion; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Time Factors; Treatment Outcome; Tretinoin | 2007 |
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pe
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Child; Child, Preschool; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prospective Studies; Remission Induction; Syndrome; Translocation, Genetic; Treatment Outcome; Tretinoin | 1997 |
Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Combined Modality Therapy; Female; Humans; Idarubicin; Immunologic Factors; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Remission Induction; RNA, Messenger; RNA, Neoplasm; Tretinoin | 1998 |
Tumour kinetics in multiple myeloma before, during, and after treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cell Count; Cell Division; Cyclophosphamide; Dexamethasone; Female; Gene Rearrangement; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunoglobulin Heavy Chains; Kinetics; Leukapheresis; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Neoplasm, Residual; Neoplastic Cells, Circulating; Transplantation, Autologous | 2001 |
24 other study(ies) available for idarubicin and Minimal Disease, Residual
| Article | Year |
|---|---|
Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Topics: Adolescent; Adult; Aged; Alleles; Allografts; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Progression-Free Survival; Recurrence; Risk Assessment; Young Adult | 2020 |
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Vidarabine | 2019 |
Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease.
Topics: Acute Disease; Adolescent; Adult; Child; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia; Male; Middle Aged; Neoplasm, Residual; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning | 2019 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Child; Child, Preschool; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Drug Monitoring; Etoposide; Female; Humans; Idarubicin; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mutation; Neoplasm, Residual; Proto-Oncogene Proteins; RUNX1 Translocation Partner 1 Protein; Survival Analysis; Transcription Factors; Translocation, Genetic | 2015 |
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Topics: Adult; Aged; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction | 2017 |
Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Dosage; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Proto-Oncogene Proteins; Recurrence; Remission Induction; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2008 |
Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Leukemia, Monocytic, Acute; Male; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Remission Induction | 2010 |
Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome | 2003 |
Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; DNA, Neoplasm; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Remission Induction; Treatment Outcome; Tretinoin | 2004 |
Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA-Binding Proteins; Etoposide; GTPase-Activating Proteins; Histone-Lysine N-Methyltransferase; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Proto-Oncogenes; RNA, Messenger; Transcription Factors | 2005 |
TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t(16;21)(p11;q22) and monitoring of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosome Mapping; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Cytarabine; Etoposide; Exons; Humans; Idarubicin; Infant; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA-Binding Protein FUS; Translocation, Genetic; Treatment Outcome | 2005 |
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin | 2005 |
Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Drug Evaluation; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia-Lymphoma, Adult T-Cell; Male; Methylprednisolone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thiotepa; Topotecan; Treatment Outcome; Vidarabine; Vinblastine | 2005 |
[Bulky lymphadenopathy in acute myeloid leukemia with inv (16) (p13q22): a case report].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid; Lymphatic Diseases; Male; Neoplasm, Residual; Prognosis | 2006 |
Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Clinical Trials as Topic; Computer Systems; Disease-Free Survival; DNA, Complementary; Drug Monitoring; Female; Follow-Up Studies; Gene Dosage; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Predictive Value of Tests; Recurrence; Remission Induction; Risk Assessment; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; Sensitivity and Specificity; Survival Analysis; Tretinoin | 2007 |
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Examination; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Organ Specificity; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2007 |
Aggressive chemotherapy for acute leukemia relapsed after transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Humans; Idarubicin; Italy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Tretinoin; Vincristine | 1994 |
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Differentiation; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Immunologic Factors; Leukemia, Promyelocytic, Acute; Life Tables; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Neutropenia; Nuclear Proteins; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Analysis; Transcription Factors; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins | 1995 |
Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prognosis; Prospective Studies; Remission Induction; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Tretinoin | 1997 |
Interferon may reduce minimal residual disease of acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Interferons; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Recurrence; Remission Induction; Tretinoin | 2000 |
Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Evaluation; Drug Synergism; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Pilot Projects; Prospective Studies; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Treatment Outcome | 2001 |